FDA Approves NEOSTIGMINE METHYLSULFATE — Gland Pharma Limited
Gland Pharma Limited announced that the FDA has approved the ANDA for Neostigmine Methylsulfate, a cholinesterase inhibitor indicated for the reversal of neuromuscular blockage following surgery. This approval allows for the intravenous launch of the generic, offering the U.S. market a bioequivalent alternative and enabling the manufacturer to target competitive share in this critical perioperative care space.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed